UBS Group
AGIO icon

UBS Group’s Agios Pharmaceuticals AGIO Stock Holding History

UBS Group’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-12,500
Closed -$542K – 8938
2020
Q4 		$542K Hold
12,500
– – ﹤0.01% 4540
2020
Q3 		$438K Buy
+12,500
New +$548K ﹤0.01% 4296
2020
Q2 		– Sell
-9,300
Closed -$330K – 7898
2020
Q1 		$330K Buy
+9,300
New +$430K ﹤0.01% 4319
2015
Q1 		– Sell
-1,400
Closed -$157K – 8735
2014
Q4 		$157K Buy
+1,400
New +$125K ﹤0.01% 5267

Other funds holding AGIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

UBS Group's AGIO Position: Q1 2026 in Review

UBS Group increased its Agios Pharmaceuticals (AGIO) stake by 4.6% in Q1 2026, buying an estimated $167K and bringing the position to 132,540 shares worth $4.48M. The position accounts for ﹤0.01% of the portfolio, ranked #4180.

UBS Group first reported a position in AGIO in Q4 2014 and has held it in 46 quarters since. The position peaked at $16.6M in Q4 2014. 233 funds tracked by Wall St. Rank hold AGIO as of Q1 2026.

  • UBS Group held 132,540 shares of Agios Pharmaceuticals worth $4.48M as of Q1 2026.
  • UBS Group bought 5,875 Agios Pharmaceuticals shares in Q1 2026, an estimated $167K.
  • Agios Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #4180 holding.
  • UBS Group first reported a position in Agios Pharmaceuticals in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's Agios Pharmaceuticals position peaked at $16.6M in Q4 2014.
  • 233 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.